Helsinki-based startup MONCYTE Health has raised €1 million in a seed investment round to fund its go-to-market strategy for personalised treatments for high cholesterol patients. The funding was led by the Finnish venture capital investors Inventure, as well as Almaral and Athensmed. The company announced the news on its website.

About MONCYTE Health

  • MONCYTE Health, co-founded by Simon Pfisterer and Tamara Alagirova,  uses proprietary technology to measure individual differences in lipid uptake and storage, helping deal with cardiovascular disease.

  • Cardiovascular disease is the leading cause of death globally, with high cholesterol being a significant risk factor. It can lead to atherosclerotic plaques, causing heart attacks and strokes.

  • The company quantifies cellular processes affecting biomarkers, providing unique insight for optimal treatment strategies and overcoming traditional medication trial-and-error methods.

‘We are extremely happy to receive this funding, which will support the development of our unique diagnostic technology and can make a real difference in improving health. We believe that personalized approaches for more effective lipid-lowering therapy and better insights into how immune cells accelerate plaque development can prevent heart attack and stroke more effectively,’ said Tamara Alagirova, CEO and co-founder at MONCYTE Health. 

Investment details

  • The funding round was co-lead by Inventure, a venture capital firm with headquarters in Helsinki and Stockholm that concentrates on investments in the Nordic and Baltic regions.

  • It was also joined by Almaral, a Finnish fund investing in early-stage biotechnology and life sciences startups, and Athensmed, a group of angels investing in seed-stage growth companies.

With this investment, we are excited to help support taking this innovative technology to the market, in close co-operation with major pharmaceutical companies and health clinics. We will leverage our strong networks to support MONCYTE Health in enhancing its global footprint and driving further success, said Sami Lampinen, Founding Partner at Inventure.

  • The round also included University of Helsinki Funds, private European investors, and Business Finland grants.

AIN reminds that in July this year, Inventure also invested in Valo.ai, a software development company developing an AI-native tool for Salesforce that uses automation in SaaS services to identify and remedy misconfigurations at their root.